-+ 0.00%
-+ 0.00%
-+ 0.00%

Cellbion wins South Korea IND clearance for phase 3 prostate cancer trial of Lu-177 DGUL

PUBT·09/28/2026 22:40:50
Listen to the news
Cellbion wins South Korea IND clearance for phase 3 prostate cancer trial of Lu-177 DGUL
  • Cellbion secured South Korea MFDS clearance to start a Phase 3 trial of Lutetium-177 DGUL in metastatic castration-resistant prostate cancer.
  • The study targets 150 patients in Korea, testing add-on Lutetium-177 DGUL versus best supportive care or standard of care.
  • Approval date: Sept. 28, 2026; planned study completion: Jan. 31, 2030.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cellbion Co. Ltd. published the original content used to generate this news brief via DART, the regulatory disclosure system operated by the South Korea Financial Supervisory Service (FSS) (Ref. ID: 20260929900003), on September 29, 2026, and is solely responsible for the information contained therein.